Skip to Content
Morningstar
Get 14 Days Free

Thermo Fisher Scientific Inc TMO

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Thermo Fisher Scientific Sees Strong Performance in Q1 as Vaccines Contribute to COVID-19 Windfall

Alex Morozov, CFA Regional Director

Analyst Note

| Alex Morozov, CFA |

We are maintaining our fair value estimate for wide-moat Thermo Fisher Scientific following the release of first-quarter results. The company delivered strong performance, with healthy recovery in the base business (up 13% organically), supported by $2.9 billion in COVID-19 pandemic response revenue. The shares appear fairly valued at current levels.

Read Full Analysis

Company Profile

Business Description

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).

Contact
168 Third Avenue
Waltham, MA, 02451
T +1 781 622-1000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Mar 31, 2021
Fiscal Year End Dec 31, 2021
Stock Type Aggressive Growth
Employees 75,000

Related

Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
Funds focus purchases in basic materials and consumer sectors.
Nupur Balain
Stock Strategist Industry Reports
Coronavirus Vaccine Progress Accelerates
Diagnostic testing, treatment, and a coronavirus vaccine could allow near-normal distancing and nonessential business recovery by mid-2021.
Karen Andersen
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
Stock-pickers find value in times of volatility and continue to purchase and hold high-quality names.
The Morningstar Ultimate Stock-Pickers Team
Premium Article
Stocks for the Next Decade
The future's bright for these 29 companies. Grab the shades.
Susan Dziubinski
Stock Strategist
Leader in Genomic Sequencing Illuminates the Way
Continued technology advancements and market expansion support Illumina's narrow moat.
Michael Waterhouse
Investing Specialists
Top 10 Buys and Sells by the Ultimate Stock-Pickers
A group of top managers continue to keep looking for good investment opportunities, while taking full advantage of a rising (and potentially overvalued) market to book some gains.
The Morningstar Ultimate Stock-Pickers Team
Fund Spy: Morningstar Medalist Edition
Announcing the Morningstar Fund Managers of the Year for 2013
Remarkable performances amid a remarkable year.
Michael Herbst
Credit Insights
Payrolls Not Too Hot, Not Too Cold
It appears that the corporate-bond market believes Friday's jobs report was high enough to suggest an advancing economy, but not so strong as to prompt a Fed taper.
David Sekera
Our Picks
Stuck in the Middle Not a Bad Place to Be With These Funds
A handful of analyst-recommended moderate-allocation funds have proved their mettle in good times and bad.
Adam Zoll
Credit Insights
Credit Spreads Remain Range-Bound
We are seeing an increase in idiosyncratic catalysts that are specific to an individual issuer as opposed to industry factors that affect an entire sector.
David Sekera
Quarter-End Insights
Our Outlook for the Credit Markets
Widening investment-grade credit spreads and rising interest rates lead to losses.
David Sekera
US Videos
Stocks Attractive on a Relative, But Not Absolute, Basis
Investors should keep their expectations in check with few asset classes looking particularly attractive and complacency in the marketplace, says Allocation Fund Manager of the Year David Giroux of T. Rowe Price Capital Appreciation.
Greg Carlson
Fund Spy
Announcing Morningstar's Fund Managers of the Year for 2012
These skippers shone amid a challenging market environment.
Michael Herbst
US Videos
Are Equity Fair Values Teetering on the 'Cliff'?
A lot of companies are very well positioned regardless of how the fiscal cliff gets resolved, as long as it gets resolved, says Morningstar's Heather Brilliant.
Jeremy Glaser
Fund Spy
Our 5 Nominees for Allocation Fund Manager of the Year
Success in 2012 took many forms.
Laura Pavlenko Lutton
Quarter-End Insights
Our Outlook for Health-Care Stocks
Election and potential sequestration emerge as key topics for health care.
Alex Morozov
Investing Specialists
Our Ultimate Stock-Pickers' Top 10 Buys and Sells
The decline in the equity markets created plenty of buying opportunities in the most recent period, but some of our managers seem to have jumped into energy stocks sooner than they should have.
The Morningstar Ultimate Stock-Pickers Team
US Videos
Will Life Sciences Firms Fall Off the Fiscal Cliff?
Even if the NIH is drastically cut, we don't see a doomsday scenario for these companies, and some of the industry's stronger players are now trading at attractive valuations.
Jeremy Glaser
Investing Specialists
10 High-Conviction Ultimate Stock-Picker Buys
Five-star-rated Devon Energy has been the standout buy so far for our top managers.
The Morningstar Ultimate Stock-Pickers Team
Credit Insights
Enjoy the Quiet While It Lasts
Over the course of the next month, we expect a number of events may cause a disruption in the calm we have experienced.
David Sekera